INTRODUCTION
============

Gastric cancer (GC) is the fifth most common cancer worldwide and the third leading cause of cancer-related death \[[@B1]\]. It is often diagnosed at an advanced stage and has a low 5-year survival rate \[[@B2]\]. Neoadjuvant chemotherapy (ChT) improves survival in locally advanced GC \[[@B3]\]. In 2006, the MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial showed that in patients with operable esophagogastric adenocarcinomas, a perioperative regimen of epirubicin, cisplatin, and infused 5-fluorouracil (ECF) resulted in downstaging of the disease and significantly improved both disease-free and overall survival when compared with surgery alone \[[@B3]\]. However, in the MAGIC trial, only 41.6% of the patients assigned to perioperative ChT completed all 6 cycles of ChT, with some discontinuation owing to toxic effects \[[@B4]\]. Therefore, there is a great need to identify host or tumor factors that might explain individual variation in therapeutic efficacy and toxicity.

Body composition (i.e., the proportions of skeletal muscle and fat) has been studied in several types of tumors in the context of various anti-cancer treatments. The evaluation of skeletal muscle and fat using cross-sectional computed tomography (CT) imaging is gaining popularity due to its wide availability, high precision, and low incremental costs \[[@B5]\]. Sarcopenia, which is the depletion of skeletal muscle, is associated with higher ChT toxicity and higher morbi-mortality in cancer patients, with an overall worse prognosis \[[@B6][@B7][@B8]\]. Recent reports in patients with GC demonstrate that sarcopenia is a significant predictor of ChT toxicity \[[@B4]\], worse postoperative outcomes \[[@B9][@B10][@B11][@B12][@B13]\], and reduced overall survival \[[@B11][@B14][@B15]\]. One of the reasons for the variable ChT toxicity among individuals may be different body composition, which is not currently taken into account when prescribing ChT.

Not only skeletal muscle mass depletion but also the distribution of adipose tissue might influence survival \[[@B16]\]. The presence of both sarcopenia and obesity has been associated with worse prognosis in a series of reports \[[@B5][@B16][@B17]\]. In the specific setting of GC, sarcopenic obesity was shown to be an independent predictive factor of postoperative complications in patients undergoing radical gastrectomy \[[@B18][@B19]\].

The aim of this study was to assess the prevalence of sarcopenia and sarcopenic obesity in a population of patients with GC, as well as its association with ChT toxicity, response, and long-term outcomes.

MATERIALS AND METHODS
=====================

We conducted a single-center retrospective study in a secondary care hospital --- Hospital Beatriz Ângelo (HBA). The study protocol was approved by the Scientific and Ethics Committee of HBA. The requirement for informed consent from patients was waived because of the retrospective design of the study.

Patients {#sec1}
--------

We selected all patients diagnosed between January 2012 and December 2014 with locally advanced adenocarcinoma from the stomach or gastroesophageal junction (GEJ, Siewert type III only) who received neoadjuvant ChT in our institution. Locally advanced gastric/GEJ cancer was defined as tumor stage greater than cT2 or positive locoregional lymph nodes (cN+), according to the tumor, node, and metastasis (TNM) staging classification (American Joint Committee on Cancer). Included patients had histologically confirmed adenocarcinoma with no evidence of distant metastasis on preoperative staging. CT was performed at diagnosis in all cases. Endoscopic ultrasound was used to confirm T stage in the absence of suspicious lymph nodes. Staging laparoscopy was not uniformly used in this cohort of patients because it was not yet systematically included in the staging protocol of our unit at that time.

Patient data were obtained from the electronic records at HBA. Demographic and clinical data, such as age, sex, tumor site and histological type, ChT regimens used, and ChT response and toxicity, were retrieved. ChT toxicity was graded according to National Cancer Institute Common Toxicity Criteria. Dose-limiting toxicity (DLT) was defined as any grade 3/4 toxicity associated with physician-ordered dose reduction or termination of therapy. Response to ChT was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria \[[@B20]\] and confirmed on surgical specimens (when available). Date of the last follow-up and date and cause of death were collected. Overall survival was measured from the date of histologic diagnosis until the date of death from any cause.

Body composition evaluation {#sec2}
---------------------------

Weight and height at diagnosis were recorded by hospital staff. Body mass index (BMI) was calculated as weight (kg)/height (m^2^).

CT scans were obtained and evaluated for body composition data by one investigator (SV) who was blinded to clinical and endoscopic data to ensure objective interpretation of image findings. Skeletal muscle and fat tissue cross-sectional areas were measured on axial CT images, at the level of the third lumbar vertebra (L3) with the patient lying supine ([Fig. 1](#F1){ref-type="fig"}). Skeletal muscle area (SMA), visceral fat area (VFA), and subcutaneous fat area (SFA) were measured in square centimeters on the basis of the pixel count using appropriate software \[[@B21]\]. Mean muscle radiation attenuation (MA) was calculated for muscle area and was also recorded. Skeletal muscle and visceral fat were normalized for height to obtain the skeletal muscle index (SMI) and visceral fat mass index (VFI) --- cm^2^/m^2^. Sarcopenia was defined as SMI lower than 41 cm^2^/m^2^ in women or lower than 43 cm^2^/m^2^ in men with BMI \<25 kg/m^2^ and \<53 cm^2^/m^2^ in men with BMI ≥25 kg/m^2^, as described by Martin et al. \[[@B21]\]. Sarcopenic obesity was defined as sarcopenia in patients with BMI ≥25 kg/m^2^.

![Axial CT images of the third lumbar vertebra region. CT was analyzed for muscle and fat tissue cross sectional areas and analyzed using appropriate software. SMA (shown in red) was quantified within a HU range of −29 to 150, VFA (shown in yellow) ranged from −150 to −50 HU, and SFA (shown in blue) ranged from −190 to −30 HU.\
CT = computed tomography; SMA = skeletal muscle area; HU = Hounsfield unit; VFA = visceral fat area; SFA = subcutaneous fat area.](jgc-17-74-g001){#F1}

Body composition data were evaluated at the time of cancer diagnosis using the CT scan performed for staging. We were also able to access a follow-up CT scan after completion of neoadjuvant ChT in a subset of 43 patients. These scans were used to perform a longitudinal analysis of body composition over time. The mean interval (± standard deviation \[SD\]) between CT scans was 86.4±29.0 days.

Statistical analysis {#sec3}
--------------------

All continuous variables were described as median and range, while categorical variables were expressed as frequency and percentage. Differences in mean continuous variables with a normal distribution were analyzed using an independent Student\'s t-test. The other continuous variables were compared using the Mann-Whitney U test. To explore univariate associations in the distribution of categorical data, the χ^2^ test or Fisher\'s exact test was used as appropriate. On multivariate analysis, treatment termination was used as the dependent variable, since we considered this variable the most clinically relevant. Any variable with a P-value \<0.250 on univariate analysis or that was considered clinically relevant was included, and variable selection was performed with a stepwise analysis. Logistic regression was used for dichotomous outcomes, in order to determine the effect estimates, which are presented as odds ratio (OR) and 95% confidence intervals (CI). It is noteworthy that all patients with sarcopenic obesity experienced early treatment termination, so a high OR was obtained, and it was not possible to calculate the upper 95% CI limit. For this reason, this variable was not included in the final model to avoid error in parameter estimation. For continuous variables in the model, cubic spline graphs and the Wald test of linearity were used to test linearity in the logit model. For the Wald test of linearity, age and MA did not demonstrate statistically significant P-values (P=0.430 and P=0.270, respectively). However, linearity was not clear for both MA and age on cubic spline graphs, so these variables were categorized. Age was categorized using 65 years as a cut-off. MA was categorized with a cut-off (35 Hounsfield units \[HUs\]) provided by cubic spline graph analysis. Survival curves were estimated using the Kaplan-Meier method and compared using a log-rank test. A P-value \<0.05 was considered statistically significant. Statistical analysis was performed using Statistical Package for Social Sciences version 22 (SPSS Inc., Chicago, IL, USA) and R software (R Foundation, Vienna, Austria).

RESULTS
=======

A total of 160 cases of gastric/GEJ (Siewert type III) cancers were diagnosed in our institution during the study period, of which 48 were locally advanced cancers treated with neoadjuvant ChT. Survival was 93.8% at 3 months, 62.5% at 1 year, and 41.7% at 2 years. Response to neoadjuvant ChT was observed in 30 patients (63%), with 3 cases of complete pathological response (6%). DLT was observed in 22 patients (46%), among whom 17 patients (35%) terminated ChT early (i.e., before completion of 3 cycles of neoadjuvant ChT).

Mean BMI at diagnosis was 23.8±3.5 kg/m^2^, with 42% of patients categorized as overweight (BMI 25--29 kg/m^2^) or obese (BMI ≥30 kg/m^2^). Body composition data at diagnosis are shown in [Table 1](#T1){ref-type="table"}. Sarcopenia was present in 23% and sarcopenic obesity in 10% of patients at diagnosis. We did not find a significantly higher proportion of sarcopenia in older patients, but patients older than 65 years had a lower value of MA (30.0±6.0 vs. 39.8±8.1 HU; P=0.001). We also assessed patient demographics and body composition characteristics according to the presence/absence of sarcopenia ([Table 2](#T2){ref-type="table"}). Sarcopenic patients were more frequently female (64% vs. 22%; P=0.023), but were otherwise similar with respect to age, tumor site, histology and stage of disease, BMI, VFI, and MA. We found no significant association between ChT response and the presence of sarcopenia or sarcopenic obesity.

###### Body composition data at diagnosis

![](jgc-17-74-i001)

  Variables            Values (n=48)             
  -------------------- ------------------------- ---------
  BMI (kg/m^2^)        23.8±3.5                  
                       Underweight (BMI \<20)    5 (10)
                       Normal (BMI 20--24)       23 (48)
                       Overweight (BMI 25--29)   18 (38)
                       Obese (BMI ≥30)           2 (4)
  SMI (cm^2^/m^2^)     48.7±9.7                  
                       Men                       52±9
                       Women                     41±7
  FMI (cm^2^/m^2^)     50.4±36.3                 
                       Men                       59±39
                       Women                     33±23
  MA (HU)              34.2±7.9                  
  Sarcopenia           11/47 (23)                
  Sarcopenic obesity   5/47 (10)                 

Values are presented as number of patients (%) or mean±SD.

BMI = body mass index; SMI = skeletal muscle index; FMI = fat mass index; MA = muscle radiation attenuation; HU = Hounsfield unit; SD = standard deviation.

###### Patient demographics according to the presence/absence of sarcopenia

![](jgc-17-74-i002)

  Variables                                  Sarcopenia (n=11)                        Non-sarcopenia (n=36)   P-value    
  ------------------------------------------ ---------------------------------------- ----------------------- ---------- -------
  Age (yr)^\*^                               69.3±9.1                                 67.1±10.4               0.534      
  Sex                                                                                                         0.023      
                                             Male                                     4                       28         
                                             Female                                   7                       8          
  Tumor site                                                                                                  0.924      
                                             Body                                     5                       18         
                                             Antrum                                   5                       14         
                                             Esophagogastric junction (Siewert III)   1                       4          
  Histology                                                                                                   0.111      
                                             Intestinal                               6                       27         
                                             Diffuse                                  5                       6          
                                             Mixed                                    0                       3          
  Clinical TNM stage                                                                                          0.322      
                                             II                                       0                       5          
                                             III                                      11                      31         
  Type of ChT used                                                                                            0.388      
                                             ECF/EOF/EOX/ECX                          2/0/6/0                 9/2/17/1   
                                             XELOX/FOLFOX/Xeloda/DCF                  1/0/1/1                 6/1/0/0    
  ChT response                                                                                                1.000      
                                             Yes                                      7                       22         
                                             No                                       4                       14         
  ChT toxicity                                                                                                           
                                             Grade 2/3/4                              3/6/0                   11/14/0    0.455
                                             Type: GI/hematological/other             5/2/3                   12/12/4    0.135
  DLT                                        7                                        14                      0.181      
  Early termination of ChT due to toxicity   7                                        10                      0.069      
  BMI(kg/m^2^)                               22.7±3.6                                 24.0±3.3                0.278      
  FMI(cm^2^/m^2^)                            39.1±34.0                                53.9±36.7               0.241      
  MA (HU)                                    31.2±7.4                                 35.1±8.0                0.151      
  Follow-up (mo)^†^                          10 \[6--36\]                             20 \[9.25--33.75\]      0.551      

TNM = tumor, node, and metastasis; ChT = chemotherapy; ECF = epirubicin, cisplatin, and 5-fluorouracil; EOF = epirubicin, oxaliplatin, and 5-fluorouracil; EOX = epirubicin, oxaliplatin, and capecitabine; ECX = epirubicin, cisplatin, and capecitabine; XELOX = capecitabine plus oxaliplatin; FOLFOX = folinic acid plus 5-fluorouracil plus oxaliplatin; Xeloda = capecitabine; DCF = docetaxel, cisplatin, and 5-fluorouracil; GI = gastrointestinal; DLT = dose-limiting toxicity; BMI = body mass index; FMI = fat mass index; MA = muscle radiation attenuation; HU = Hounsfield unit; SD = standard deviation; IQR = interquartile range.

Values are presented differently follow as ^\*^mean±SD; ^†^median \[IQR\].

Although not statistically significant, we found a trend toward a higher percentage of DLT in patients with sarcopenia (64% vs. 39%; P=0.181) and sarcopenic obesity (80% vs. 42%; P=0.165). We found an association between early termination of ChT and the presence of sarcopenia (64% vs. 28%; P=0.069) and sarcopenic obesity (100% vs. 28%; P=0.004). Seven of 11 patients with sarcopenia (64%) and all patients with sarcopenic obesity (n=5) required early ChT termination.

Univariate and multivariate analysis were performed to assess factors that could contribute to termination of treatment ([Table 3](#T3){ref-type="table"}). On univariate analysis, both sarcopenia and MA were associated with treatment termination. Additionally, a strong effect was found for sarcopenic obesity, since treatment termination was observed in all patients with sarcopenic obesity. There was no significant association between disease stage and termination of treatment.

###### Univariate and multivariate analysis assessing the OR of treatment termination associated with clinical variables and body composition markers in patients with GC

![](jgc-17-74-i003)

  Variables            Univariate analysis   Multivariate analysis                                                             
  -------------------- --------------------- ----------------------- ----------------- ------------------ ------ ------------- -------
  Age (yr)                                                                                                                     
                       \<65                  1.00                                      0.920              1.00                 0.308
                       ≥65                   1.06                    0.30--3.81                           0.44   0.08--2.08    
  Sex                                                                                  Excluded                                
                       Male                  1.00                                      0.700                                   
                       Female                1.27                    0.34--4.50                                                
  Tumor site                                                                                                                   
                       Body                  1.00                                      0.420                                   
                       Antrum/GEJ            1.63                    0.49--5.61                                                
  Stage                                                                                Excluded                                
                       II                    1.00                                      0.260                                   
                       III                   0.33                    0.04--2.23                                                
  Histology type                                                                       Excluded                                
                       Intestinal            1.00                                      0.640                                   
                       Diffuse/mixed         1.36                    0.34--5.24                                                
  SMA                  0.98                  0.96--1.00              0.250             Excluded                                
  VFA                  1.00                  0.99--1.01              0.120             Excluded                                
  SFA                  1.00                  0.99--1.01              0.280             Excluded                                
  MA (HU)                                                                                                                      
                       \<35                  1.00                                      0.040              1.00                 0.040
                       ≥35                   0.27                    0.06--0.95                           0.20   0.33--0.95    
  Sarcopenia                                                                                                                   
                       No                    1.00                                      0.030              1.00                 0.050
                       Yes                   4.55                    1.13--20.70                          4.23   0.98--20.80   
  Sarcopenic obesity                                                                   Not included^\*^                        
                       No                    1.00                                                                              
                       Yes                   106,362,030.9           2.81×10^−72^-NA   \<0.001                                 

OR = odds ratio; GC = gastric cancer; CI = confidence interval; GEJ = gastroesophageal junction; SMA = skeletal muscle area; VFA = visceral fat area; SFA = subcutaneous fat area; MA = muscle radiation attenuation; HU = Hounsfield unit.

^\*^All patients with sarcopenic obesity experienced treatment termination, and for that reason a high OR was obtained, and the upper 95% CI limit was not possible to calculate. This variable was not included in the final model to avoid error in parameter estimation.

On multivariate analysis, the odds of treatment termination were reduced in patients with higher MA, as compared to patients with lower MA (OR=0.20; P=0.040). In addition, the odds of treatment termination were higher in patients with sarcopenia as compared to patients without sarcopenia (OR=4.23; P=0.050). The receiver operating characteristic (ROC) curve showed an acceptable power of discrimination of treatment termination using a model with age, sarcopenia, and MA as independent variables (area under the curve \[AUC\] of 0.755) ([Fig. 2](#F2){ref-type="fig"}).

![ROC curve using treatment termination as dependent variable and age, sarcopenia, and MA as independent variables. Sensitivity: 58.8%; Specificity: 86.7%; Positive predictive value: 21.2%; Negative predictive value: 28.6%.\
ROC = receiver operating characteristic; MA = muscle radiation attenuation; AUC = area under the curve.](jgc-17-74-g002){#F2}

There was no significant difference in overall survival between patients with and without sarcopenia ([Fig. 3A](#F3){ref-type="fig"}). However, patients with sarcopenic obesity showed reduced survival (median survival 6 months \[95% CI=3.9--8.5\] vs. 25 months for patients who were obese and did not have sarcopenia \[95% CI=20.2--38.2\]; log-rank test P=0.000) ([Fig. 3B](#F3){ref-type="fig"}).

![Kaplan-Meier survival curves of patients with and without sarcopenia (A) and of obese patients with and without sarcopenia (B) (log-rank P-value).](jgc-17-74-g003){#F3}

A second CT scan after completion of neoadjuvant ChT was available in a subset of 43 patients. No second CT scan was available for 5 patients, either owing to obvious clinical disease progression or because either magnetic resonance imaging or ultrasonography was used. The mean interval (± SD) between CT scans was 86.4±29.0 days. The mean loss of SMA during follow-up (mean 86 days) was 15.4±2.8 cm^2^. In the second CT scan, sarcopenia and sarcopenic obesity were found in 38% and 17% of patients, respectively, after neoadjuvant ChT. Over time, there was a significant loss of skeletal muscle and adipose tissue ([Table 4](#T4){ref-type="table"}). Stratification of patients according to ChT response demonstrated that only those patients who did not respond to ChT experienced a significant reduction in SMI (49.9±10.1 to 44.6±9.5 cm^2^/m^2^; P=0.001) and VFI (57.5±33.6 to 42.1±26.3 cm^2^/m^2^; P=0.002) ([Fig. 4A](#F4){ref-type="fig"}). Similarly, only those patients who experienced DLT had a significant reduction in SMI (47.0±10.2 to 43.0±10.8 cm^2^/m^2^; P=0.001) and VFI (52.7±31.2 to 39.2±28.5 cm^2^/m^2^; P=0.000) ([Fig. 4B](#F4){ref-type="fig"}).

###### Change in body composition over time in patients with GC (n=43)

![](jgc-17-74-i004)

  Variables          First CT scan   Second CT scan   P-value
  ------------------ --------------- ---------------- ---------
  SMA (cm^2^)        132.1±30.9      123.9±29.6       0.001
  MA (HU)            34.0±7.2        31.7±6.7         0.006
  VFA (cm^2^)        137.8±96.2      113.5±86.4       0.001
  SFA (cm^2^)        136.2±76.3      119.6±78.7       0.002
  SMI (cm^2^/m^2^)   48.2±9.6        45.3±9.5         0.001
  VFI (cm^2^/m^2^)   49.8±34.0       41.0±30.1        0.001

Mean interval (± SD) between CT scans: 86.4±29.0 days.

GC = gastric cancer; CT = computed tomography; SMA = skeletal muscle area; MA = muscle radiation attenuation; HU = Hounsfield unit; VFA = visceral fat area; SFA = subcutaneous fat area; SMI = skeletal muscle index; VFI = visceral fat mass index; SD = standard deviation.

![Body composition changes (namely SMI and VFI in cm^2^/m^2^) before and after neoadjuvant ChT, according to ChT response (A) and DLT (B).\
SMI = skeletal muscle index; VFI = visceral fat mass index; ChT = chemotherapy; DLT = dose-limiting toxicity; NS = non-significant.](jgc-17-74-g004){#F4}

DISCUSSION
==========

In this observational study in patients with locally advanced GC who underwent neoadjuvant ChT, we observed that sarcopenic obesity was associated with poorer outcome, with a high likelihood of early termination of treatment and lower overall survival. Additionally, we confirmed that neoadjuvant ChT was associated with important catabolic losses of muscle and fat over time, although these occurred only in patients who did not respond to ChT or in those who developed toxicity.

Several recent studies have reported a high prevalence of sarcopenia at diagnosis in patients with gastrointestinal cancers ([Table 5](#T5){ref-type="table"}) \[[@B22][@B23][@B24][@B25][@B26][@B27][@B28]\]. Comparison of sarcopenia prevalence among studies is rather difficult because of the use of different methodologies: axial CT cross-sectional imaging of SMAs, muscle mass using dual-energy X-ray absorptiometry, or a combination of anthropometric and physical performance measurements \[[@B29][@B30][@B31][@B32]\]. Furthermore, even when the same methodology is employed, different cut-offs for sarcopenia are often used ([Table 5](#T5){ref-type="table"}).

###### Sarcopenia prevalence at diagnosis of gastrointestinal tumors

![](jgc-17-74-i005)

  Study reference               Country           Type of tumor              No. of patients   Sarcopenia (%)   Sarcopenia definition
  ----------------------------- ----------------- -------------------------- ----------------- ---------------- -----------------------
  Yip et al. \[[@B28]\]         United Kingdom    Esophageal cancer          35                26.0             1
  Reisinger et al. \[[@B27]\]   The Netherlands   Esophageal cancer          108               56.0             1
  Awad et al. \[[@B6]\]         United Kingdom    Esophagogastric cancer     47                57.0             1
  Tan et al. \[[@B4]\]          United Kingdom    Esophagogastric cancer     89                49.4             1
  Tegels et al. \[[@B36]\]      The Netherlands   GC                         152               57.7             2
  Huang et al. \[[@B9]\]        China             GC                         470               16.8             3
  Chen et al. \[[@B10]\]        China             GC                         158               24.7             3
  Zhuang et al. \[[@B11]\]      China             GC                         937               41.5             4
  Wang et al. \[[@B12]\]        China             GC                         255               12.5             5
  Hayashi et al. \[[@B14]\]     Japan             GC                         53                69.8             2
  Huang et al. \[[@B15]\]       China             GC                         173               30.1             3
  Fukuda et al. \[[@B13]\]      Japan             GC                         99                21.2             6
  Nishigori et al. \[[@B19]\]   Japan             GC                         157               57.0             1
  Lieffers et al. \[[@B22]\]    Canada            Colorectal cancer          234               39.0             1
  Reisinger et al. \[[@B24]\]   The Netherlands   Colorectal cancer          310               47.7             1
  Huang et al. \[[@B30]\]       China             Colorectal cancer          142               12.0             5
  Tan et al. \[[@B23]\]         Canada            Pancreatic cancer          111               56.0             1
  Peng et al. \[[@B8]\]         USA               Pancreatic cancer          557               25.0             7
  Joglekar et al. \[[@B25]\]    USA               Pancreatic cancer          118               26.3             8
  Harimoto et al. \[[@B26]\]    Japan             Hepatocellular carcinoma   186               40.3             9

Sarcopenia definition:

SMI ≤38.5 cm^2^/m^2^ for women and ≤52.4 cm^2^/m^2^ for menSMI \<41 cm^2^/m^2^ for women and \<43 cm^2^/m^2^ in men with BMI \<25 kg/m^2^ and \<53 cm^2^/m^2^ in men with BMI ≥25 kg/m^2^SMI \<34.9 cm^2^/m^2^ for women and ≤40.8 cm^2^/m^2^ for men plus handgrip strength \<18 kg for women and \<26 kg for men and/or 6-m usual gait speed \<0.8 m/sSMI \<34.9 cm^2^/m^2^ for women and ≤40.8 cm^2^/m^2^ for menSMI \<29 cm^2^/m^2^ for women and ≤36 cm^2^/m^2^ for men plus handgrip strength \<18 kg for women and \<26 kg for men and/or 6-m usual gait speed \<0.8 m/sSMI \<6.42 kg/m^2^ for women and ≤8.87 kg/m^2^ for men plus handgrip strength \<20 kg for women and \<30 kg for men and/or 6-m usual gait speed \<0.8 m/sTotal psoas muscle index \<362 mm^2^/m^2^ for women and \<492 mm^2^/m^2^ for menTotal psoas muscle index \<4.0 cm^2^/m^2^ for women and \<5.2 mm^2^/m^2^ for menSMI ≤41.1 cm^2^/m^2^ for women and ≤43.75 cm^2^/m^2^ for men

GC = gastric cancer; SMI = skeletal muscle index; BMI = body mass index.

In the specific setting of patients with GC, the reported prevalence in the literature of sarcopenia ranges from 12.5% to 69.8% at diagnosis ([Table 5](#T5){ref-type="table"}). In our population, a quarter of the patients had sarcopenia at diagnosis. Additionally, the prevalence of sarcopenia increased following neoadjuvant ChT. Similarly, Awad et al. \[[@B6]\] reported an increase in sarcopenia prevalence from 57% pre-ChT to 79% in patients with esophagogastric cancer.

Several recent studies show a relationship between skeletal muscle mass depletion and treatment toxicity. In a recent systematic review by Kazemi-Bajestani et al. \[[@B33]\], there were 14 published articles relating CT-based body composition to the prevalence of ChT-induced toxicity. These were mainly single-center investigations with small samples, \[[@B33]\] and only one addressed patients with GC \[[@B4]\]. In a prospective study in patients with colon cancer by Prado et al. \[[@B7]\], the authors found an increase in DLT in patients with lower muscle mass treated with 5-fluorouracil (5-FU). Likewise, in a prospective randomized trial in patients with colon cancer by Ali et al. \[[@B34]\], low lean body mass was an independent predictor of DLT and neuropathy in patients administered folinic acid plus 5-fluorouracil plus oxaliplatin (FOLFOX)-based regimens. More recently, data analysis from a randomized controlled trial in advanced non-small cell lung cancer also showed an association between low muscle mass and ChT-induced hematological toxicity \[[@B35]\].

However, studies addressing the impact of sarcopenia in ChT toxicity in patients with GC are scarce. Recently, Tan et al. \[[@B4]\] demonstrated that sarcopenia at the time of diagnosis in patients with esophagogastric cancer was a significant predictor of DLT. In the present study, we found that the odds of treatment termination were higher in patients with sarcopenia. The mechanism that links sarcopenia with increased ChT toxicity is currently unknown. Some authors speculate that different proportions of lean and adipose tissue compartments may be associated with alterations in the distribution, metabolism, and clearance of ChT agents \[[@B7]\].

Although the impact of sarcopenia in DLT in patients with GC needs further prospective characterization, there are several recent reports demonstrating the important predictive role of low muscle mass in short- and long-term outcomes in patients with GC. In patients who undergo radical gastrectomy for GC, there is a significant relationship between sarcopenia and postoperative complications \[[@B10][@B11][@B12][@B13][@B30]\]. In a recent prospective study by Huang et al. \[[@B15]\] including 173 elderly patients undergoing curative gastrectomy for GC, sarcopenia was predictive of higher 1-year mortality (hazard ratio \[HR\]=3.615; 95% CI=1.459--8.957). Similarly, a large retrospective study of 937 patients with GC showed that sarcopenia was an independent predictor of low overall survival after gastrectomy \[[@B11]\]. Nonetheless, it is important to highlight that the impact of sarcopenia in postoperative and long-term outcomes has not been universally reported \[[@B36]\]. Further prospective studies using a consensual definition for sarcopenia are needed.

Although cachexia is a frequent feature of patients with advanced cancer, a substantial increase has been observed in the past decades in the proportion of cancer patients with a BMI in the overweight range \[[@B37]\]. In the present study, 42% of patients were overweight or obese at the time of diagnosis of GC. Abdominal adipose fat distribution might have an influence on tumor growth and therefore on cancer outcome \[[@B16]\]. The negative impact of visceral obesity has been previously reported in patients with colon, pancreatic, and renal cancer \[[@B38][@B39][@B40]\]; however, few studies in GC have addressed this issue.

The simultaneous presence of sarcopenia and obesity (especially visceral obesity) is a worst-case scenario associated with poorer prognosis \[[@B5]\]. The inflammatory cytokines produced by adipose cells are thought to play an important role in insulin resistance, resulting in an increase in muscle protein loss \[[@B41]\]. In addition, in patients with sarcopenic obesity, the increased body mass inflates the overall administered ChT dose, which is then distributed within a reduced lean tissue compartment, thus resulting in a disproportionately small volume of drug distribution and hence higher toxicity \[[@B5]\]. A population-based study by Prado et al. \[[@B5]\] that included 250 obese patients with solid tumors of the respiratory and gastrointestinal tracts showed that patients with sarcopenic obesity had poorer functional status and lower survival. In a recent prospective study of 206 overweight or obese patients with GC after radical gastrectomy, sarcopenic obesity was an independent predictor of postoperative complications \[[@B18]\]. Likewise, Nishigori et al. \[[@B19]\] retrospectively reported a prevalence of 24% of sarcopenic obesity (45 of 157 patients with GC) and found an association between sarcopenic obesity and surgical site infection.

Limitations of our study include its retrospective design, single-center recruitment, and small sample size. One important limitation was the lack of staging laparoscopy that is now routinely used in our unit. Some of the patients included in the study might have already had peritoneal disease, and this may explain the notable percentage of patients with disease progression during neoadjuvant ChT. Another important limitation, associated with the retrospective nature of the study, was the use of different regimens of ChT drugs according to patient characteristics. Nonetheless, 77% of our cohort received ECF or a similar regimen, with no difference between patients with and without sarcopenia. The relationship between ChT toxicity and body composition has been observed in patients receiving a variety of different ChT regimens \[[@B35][@B42]\]. One possible explanation is that the measurements of body composition reveal reduced fitness and low ability to tolerate cancer therapy independently of the type of ChT.

CONCLUSIONS
===========

Sarcopenic obesity is a strong risk factor for ChT toxicity, premature termination of ChT, and reduced overall survival. Future studies are required to define ChT dosages that are within the limits of tolerability for this unique and vulnerable subgroup.
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